Natera Partners With Aveta Biomics On Phase 3 Head And Neck Cancer Trial

Natera and Aveta Biomics announced a partnership supporting AVTA 30-01, Aveta's Phase 3 trial of the immunotherapy candidate APG-157 in locally advanced patients. The collaboration adds testing support for a late-stage oncology program, a constructive development for both companies. The announcement is largely company-specific and is unlikely to have broad market impact.

Analysis

Natera and Aveta Biomics announced a partnership supporting AVTA 30-01, Aveta's Phase 3 trial of the immunotherapy candidate APG-157 in locally advanced patients. The collaboration adds testing support for a late-stage oncology program, a constructive development for both companies. The announcement is largely company-specific and is unlikely to have broad market impact.